Regulators Stop Eye Drop Manufacturing At Major Indian Pharmaceutical Plant

Regulators suspended eye medicine manufacturing at a major pharmaceutical plant over quality lapses.

Indian authorities have directed the nation's largest pharmaceutical company to suspend ophthalmic medicine manufacturing at a production facility in Assam. The intervention follows identified quality control failures at the site. Operations will remain on hold until inspectors approve a comprehensive compliance remediation plan.

• The company affectedSun Pharma holds the position of the largest drug manufacturing enterprise across India.
• The triggerRegulators intervened following inspections that uncovered significant manufacturing standards violations.
• The requirementProduction lines will stay closed until safety audits satisfy official oversight bodies.